Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
TELA Bio, Inc. (TELA)
|
Add to portfolio |
|
|
|
| Price: |
$13.10
| | Metrics |
| OS: |
24.5
|
M
| |
-109
|
% ROE
|
| Market cap: |
$321
|
M
| |
-238
|
% ROIC
|
|
Net cash:
|
$25.1
|
M
| |
$1.02
|
per share
|
|
EV:
|
$296
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($40.1)
|
M
| |
|
|
|
EBIT
|
($40.5)
|
M
| |
|
|
| EPS |
($2.34)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 41.4 | 29.5 | 18.2 | 15.4 | 8.3 | 4.2 |
| Revenue growth | 40.6% | 61.8% | 17.9% | 86.7% | 94.9% | |
| Cost of goods sold | 0.8 | 0.3 | 0.3 | 0.3 | 0.8 | 1.7 |
| Gross profit | 40.6 | 29.2 | 17.9 | 15.1 | 7.5 | 2.5 |
| Gross margin | 98.1% | 99.0% | 98.3% | 98.0% | 90.5% | 59.6% |
| Sales and marketing | 43.3 | 29.1 | 22.1 | 18.1 | 13.6 | 8.7 |
| Research and development | 8.9 | 6.7 | 4.3 | 4.2 | 4.3 | 5.8 |
| General and administrative | 13.9 | 12.5 | 10.1 | 6.2 | 4.9 | 5.0 |
| EBIT | -39.0 | -29.5 | -25.3 | -19.2 | -17.8 | -16.9 |
| EBIT margin | -94.2% | -100.0% | -138.8% | -124.1% | -214.9% | -398.7% |
| Pre-tax income | -44.3 | -33.3 | -28.8 | -22.4 | -21.1 | -21.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -44.3 | -33.3 | -28.8 | -30.2 | -29.9 | -27.2 |
| Net margin | -106.9% | -112.9% | -158.1% | -195.6% | -361.6% | -641.4% |
| |
| Diluted EPS | ($2.72) | ($2.30) | ($2.23) | ($17.10) | ($101.41) | ($93.25) |
| Shares outstanding (diluted) | 16.3 | 14.5 | 12.9 | 1.8 | 0.3 | 0.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|